Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93607Research ArticleMozgovoy insul't: vzglyad iz terapevticheskogo oknaDrapkinaO. M-15102011131011912228122021Copyright © 2011, Consilium Medicum2011[Neyer J et al. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69–e171.][Bonita R. Epidemiology of stroke. Lancet 1992; 339: 342–4.][Qizilbash N et al. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet 1995; 346: 1647–53.][Culic V.J. Excess in cardiovascular events on Mondays: could atherosclerotic plaques be more vulnerable after the weekend because of alcohol related cytokine dysregulation? Epidemiol Community Health 2005; 59: 911.][Zipes, Braunwald et al. Braunwald’s Heart Disease, 7e.][Скворцова В.И. Артериальная гипертония и цереброваскулярные нарушения. Руководство по артериальной гипертонии. Под ред. Е.И.Чазова, И.Е.Чазовой. М.: Медиа Медика, 2005.][Devereux R.B., Dahlöf B, Gerdts E et al. Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial. Circulation 2004; 110: 1456–62.][Braunwald E, Domanski M.J., Fowler S.E. et al. Angiotensin - converting - enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058.][Mancini G.B.J., Henry G.C., Macaya C et al. Angiotensin - converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation 1996; 94: 258–6.][Libby P, Aikawa M. Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nat Med 2002; 8: 1257.][Pasceri V, Chang J, Willerson J.T., Yeh E.T.H. Modulation of C - Reactive Protein – Mediated Monocyte Chemoattractant Protein - 1 Induction in Human Endothelial Cells by Anti - Atherosclerosis Drugs. Circulation 2001; 103: 2531–4.][Neal B, Mac Mahon S. Randomised trial of a perindopril - based blood - pressure - lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.][Watanabe S, Tagawa T, Yamakawa K et al. Inhibition of the reninangiotensin system prevents free fatty acid - induced acute endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2005; 25: 2376–80.][de Luca N, Mallion J.M., O’Rourke M.F. et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first - line combination: the REASON echocardiography study. Am J Hypertens 2004; 17: 660–7.][Mogensen C.E., Viberti G, Halimi S et al. Effect of low - dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063–71.][Williams B, Lacy P.S., Thom S.M. et al. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure–lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study. Circulation 2006; 113: 1213–25.][Fox K.M., Henderson J.R., Bertrand M.E. et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.][Staessen J.A., Birkenhager W.H. Evidence that new antihypertensives are superior to older drugs. Lancet 2005; 366: 869–71.][Ideishi, Kikuo Arakawa, Hideko Nakashima et al. Angiotensin II Antagonist Prevents Electrical Remodeling in Atrial Fibrillation. Circulation 2000; 101: 2612–7.][Kannel W.B., Abbott R.D., Savage D.D., Mc Namara P.M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018–22.][Gerdts E, Oikarinen L, Palmieri V et al. Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2002; 39 (3): 739–43.][Healey J.S., Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin - converting enzyme inhibitors and angiotensin receptor blockers: a meta - analysis. J Am Coll Cardiol 2005; 45 (11): 1832–9.]